ストックスクリーナーアプリを入手
1.20
6.19%
0.07
プレマーケット:
1.20
前日終値:
$1.13
開ける：
$1.15
24時間の取引高:
10.19M
Relative Volume:
1.02
時価総額：
$328.64M
収益：
$188.87M
当期純損益:
$-400.38M
株価収益率:
-0.80
EPS:
-1.5
ネットキャッシュフロー:
$-260.90M
1週間 パフォーマンス:
+8.11%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
-47.83%
1年 パフォーマンス:
-28.57%
1日の値動き範囲:
$1.13
$1.23
1週間の範囲:
$1.08
$1.23
52週間の値動き範囲:
$1.06
$2.72
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
名前
Pacific Biosciences Of California Inc
セクター
電話
650-521-8000
住所
1305 O'BRIEN DRIVE, MENLO PARK, CA
PACB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.20 | 328.64M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
134.00 | 227.71B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.29 | 152.66B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.46 | 142.93B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.62 | 107.17B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
74.63 | 44.04B | 5.54B | 4.18B | 623.10M | 7.00 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-11 | ダウングレード | UBS | Buy → Neutral |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-04-22 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-04-18 | ダウングレード | Goldman | Buy → Neutral |
| 2023-12-14 | 開始されました | Guggenheim | Neutral |
| 2023-12-14 | 開始されました | Stephens | Overweight |
| 2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2023-11-17 | アップグレード | UBS | Neutral → Buy |
| 2023-10-31 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-06-30 | 開始されました | Goldman | Buy |
| 2023-05-10 | 開始されました | Barclays | Equal Weight |
| 2023-03-31 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | 開始されました | UBS | Neutral |
| 2023-01-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-01-21 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-01-06 | 再開されました | Piper Sandler | Neutral |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-09-27 | 開始されました | Canaccord Genuity | Buy |
| 2021-02-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-06-02 | 再開されました | Cantor Fitzgerald | Overweight |
| 2020-03-09 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-10-15 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | 開始されました | Cowen | Outperform |
| 2017-11-03 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | ダウングレード | CL King | Buy → Neutral |
| 2016-11-03 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2016-06-27 | 開始されました | CL King | Buy |
| 2016-04-15 | 開始されました | First Analysis Sec | Overweight |
| 2016-02-04 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2015-10-23 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-02-04 | 繰り返されました | Maxim Group | Buy |
| 2013-09-26 | 繰り返されました | Maxim Group | Buy |
| 2013-01-14 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Pacific Biosciences Of California Inc (PACB) 最新ニュース
Pacific Biosciences: Q1 Earnings Snapshot - Huron Daily Tribune
Pacific Biosciences (PACB) Reports Q1 Earnings: What Key Metrics Have to Say - Nasdaq
Pacific Biosciences (PACB) Reports Q1 2025 Financials Amid Macroeconomic Challenges - GuruFocus
PacBio (NASDAQ:PACB) Beats Expectations in Strong Q1 - Yahoo Finance
PacBio Q1 2025 slides: Consumable growth offsets instrument revenue decline - Investing.com Canada
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
PacBio Announces First Quarter 2025 Financial Results - Stock Titan
PacBio (PACB) Sees Increased Options Activity Ahead of Earnings | PACB Stock News - GuruFocus
Digital Genome Market Forecast: Growth Trends, Key Players & - openPR.com
Pacific Biosciences (PACB) Prepares for Q1 Earnings Announcement - GuruFocus
Earnings To Watch: Pacific Biosciences of California Inc (PACB) Reports Q1 2025 Result - GuruFocus
PacBio (PACB) Q1 Earnings: What To Expect - Yahoo Finance
Pacific Biosciences of California Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
PacBio (PACB) Launches Pioneering Genomic Project in Asia Pacific | PACB Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
PacBio (PACB) Q4 Earnings Report Preview: What To Look For - Barchart.com
Pacific Biosciences of California (PACB) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Pacific Biosciences Says New Technology to Enhance HiFi Sequencing - marketscreener.com
PacBio Licenses CUHK AI Tech To Boost 5-Base Methylation Detection In HiFi Sequencing - Nasdaq
PacBio (PACB) Enhances Methylation Detection in HiFi Sequencing - GuruFocus
PacBio Licenses Advanced DNA Methylation Detection Technology to Enhance HiFi Sequencing Accuracy - Nasdaq
PACB stock touches 52-week low at $1.08 amid market challenges - Investing.com Australia
Pacific Biosciences of California (PACB) Flat As Market Gains: What You Should Know - Yahoo Finance
Pacific Biosciences of California Selected by Davos Alzheimer's Collaborative as Technology Partner - marketscreener.com
PacBio partners with global Alzheimer’s initiative By Investing.com - Investing.com India
PacBio partners with global Alzheimer’s initiative - Investing.com Australia
PacBio (PACB) Joins DAC's North African Dementia Project | PACB Stock News - GuruFocus
PacBio Partners with Davos Alzheimer’s Collaborative to Advance Alzheimer's Research in North Africa - Nasdaq
Selling Pacific Biosciences of California Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - simplywall.st
PacBio (PACB) Price Target Cut Amid Sector Funding Concerns | PA - GuruFocus
Positive week for Pacific Biosciences of California, Inc. (NASDAQ:PACB) institutional investors who lost 57% over the past year - Yahoo
Pacific Biosciences of California jumps 22% after prelim Q1 results, guides FY - MSN
Canaccord maintains $3 price target on PACB, reiterates Buy By Investing.com - Investing.com South Africa
Tariffs, NIH ‘uncertainty’ force PacBio into layoffsSan Francisco Business Times - The Business Journals
Canaccord maintains $3 price target on PACB, reiterates Buy - Investing.com
PacBio outlines cost-cutting, revenue meets Q1 target By Investing.com - Investing.com South Africa
PacBio to cut jobs, lower spending over NIH funding cuts and tariffs - Reuters
Healthcare Stocks Ride a Tariffs-Relief Wave -- Healthcare Roundup - marketscreener.com
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know - The Globe and Mail
Sequencing Company PacBio Cuts Costs Amid Uncertainty Around NIH Funding And New Tariffs - Benzinga
Simply Good Foods, Pacific Biosciences of California, Kura Sushi, Delta Air Lines And Other Big Stocks Moving Higher On WednesdayAkso Health (NASDAQ:AHG), Anglogold Ashanti (NYSE:AU) - Benzinga
Pacific Biosciences of California Sees Lower Q1 Revenue, Plans Job Cuts to Reduce Costs - MarketScreener
PacBio Q1 Prel. Revenue Down, Says Met Expectations; To Cut Jobs - Nasdaq
PacBio outlines cost-cutting, revenue meets Q1 target - Investing.com
Pacbio posts Preliminary Q1 2025 Revenue And Reiterates 2025 Revenue Guidance - marketscreener.com
Pacific Biosciences of California, Inc. Reiterates Earnings Guidance for the Full Year 2025 - marketscreener.com
PacBio's Bold Move: $50M Cost Cut Plan as Q1 Shows Record Consumables Growth - Stock Titan
PacBio to cut headcount, costs in face of tariff headwinds - Fierce Biotech
PacBio Strengthens Leadership: New CFO Joins with Strategic Equity Package - Stock Titan
Customer success story: The University of Bern takes long-read sequencing to the next level with SPRQ chemistry - PacBio
Pacific Biosciences of California appoints CFO - MSN
Pacific Biosciences Of California Inc (PACB) 財務データ
収益
当期純利益
現金流量
EPS
1.04%
0.55%
大文字化:
|
ボリューム (24 時間):